New Tool to Self-Assess Severity in Atopic Dermatitis
Patient-Oriented SCORing Atopic Dermatitis index as good as physicians' index
FRIDAY, April 8 (HealthDay News) -- The Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD) index correlates well with SCORAD, which is used internationally by physicians to validate atopic dermatitis (AD) severity, and can be used by patients to self-assess their AD severity, according to a study published online March 17 in Allergy.
Jean-Francois Stalder, M.D., from the Nantes University Hospital in France, and colleagues assessed the correlation between SCORAD measured by physicians and PO-SCORAD measured by patients using the Bravis Pearson correlation coefficient (r). The severity of AD was assessed at baseline (D0) and after an average of 28 days (D28) in 471 patients (185 adults, 286 children) exhibiting all forms of AD severity.
The investigators found a significant correlation between PO-SCORAD and SCORAD scores at D0 (r = 0.67), which persisted consistently at D28 (r = 0.79) in both children and adults. Absolute changes from baseline were significantly related in both the scales (r = 0.71). Despite the absence of intervention, AD improved during the study period, with the PO-SCORAD and SCORAD scores decreasing from D0 to D28 by −19.19 and −24.39 percent, respectively.
"This study validated the use of PO-SCORAD for the self-assessment of AD in a large European population of patients exhibiting the whole range of AD severity. The PO-SCORAD correlates well with SCORAD, considered as the most internationally used AD severity assessment tool for physicians," the authors write.